Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 12—December 2024
CME ACTIVITY - Research

Ophthalmic Sequelae of Ebola Virus Disease in Survivors, Sierra Leone

Charlene H. Choo, Laura Ward, Ian Crozier, Tolulope Fashina, Daisy Yan, Brent R. Hayek, Caleb Hartley, Matthew Vandy, John G. Mattia, Lloyd Harrison-Williams, Jalikatu Mustapha, Carolyn Drews-Botsch, Steven Yeh1, and Jessica Shantha1Comments to Author 
Author affiliation: University of Nebraska Medical Center, Omaha, Nebraska, USA (C.H. Choo, T. Fashina, C. Hartley, S. Yeh); Emory University, Atlanta, Georgia, USA (L. Ward, S. Yeh, J. Shantha); Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA (I. Crozier); University of California, San Francisco, California, USA (D. Yan, J. Shantha); North Georgia Eye Clinic, Gainesville, Georgia, USA (B.R. Hayek); Ministry of Health and Sanitation, Freetown, Sierra Leone (M. Vandy, J.G. Mattia, L. Harrison-Williams, J. Mustapha); George Mason University, Fairfax, Virginia, USA (C. Drews-Botsch)

Main Article

Table 2

Medical history and current symptoms of survivors in study of ophthalmic sequelae after Ebola virus disease, Sierra Leone*

Medical history and symptoms Total, n = 521
Days admitted in ETU, median (IQR) 22 (14–30)
Days from ETU discharge to study enrollment, median (IQR) 1,289 (82)
Had previous eye exam
444 (86.6)
Medical history n = 510
Malaria 244 (47.8)
Typhoid 473 (92.7)
Lassa fever 7 (1.4)
HIV 3 (0.6)
Other 54 (10.6)
None
 10 (2.0)
Ocular history n = 510
Uveitis 51 (10.0)
Cataract
 42 (8.2)
Current systemic symptoms n = 510
Any systemic symptoms 503 (98.6)
Headache 485 (95.1)
Joint pain 427 (83.7)
Fatigue 369 (72.4)
Chest pain 316 (62.0)
Low mood 305 (59.8)
Abdominal pain 294 (57.6)
Weight loss 276 (54.1)
Joint stiffness and/or swelling 258 (50.6)
Anxiety
 235 (46.1)
Current ocular symptoms N = 510
Any eye symptoms 484 (94.9)
Eye pain 377 (73.9)
Light sensitivity 344 (67.4)
Blurred vision 342 (67.1)
Tearing 298 (58.4)
Eye redness 270 (52.9)
Floaters 152 (29.8)
Vision loss 134 (26.3)

*Values are no. (%) except as indicated. ETU, Ebola treatment unit; IQR, interquartile range.

Main Article

1These authors were co–principal investigators.

Page created: November 04, 2024
Page updated: November 22, 2024
Page reviewed: November 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external